More patent information from patft.uspto.gov website.
United States Patent 8,765,146
Bruder , et al. July 1, 2014
Adenoviral vector-based malaria vaccines
Abstract
The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as Plasmodium nucleic acid sequences, operably linked to promoters. The invention further provides a method of inducing an immune response against malaria in a mammal comprising administering the adenoviral vectors to the mammal.
Inventors: Bruder; Joseph T. (Ijamsville, MD), Kovesdi; Imre (Rockville, MD), King; C. Richter (New York, NY), McVey; Duncan L. (Derwood, MD), Ettyreddy; Damodar R. (North Potomac, MD), Doolan; Denise Louise (Camp Hill, AU), Carucci; Daniel John (Washington, DC)
Applicant:
Bruder; Joseph T.
Kovesdi; Imre
King; C. Richter
McVey; Duncan L.
Ettyreddy; Damodar R.
Doolan; Denise Louise
Carucci; Daniel John
Assignee: GenVec, Inc. (Gaithersburg, MD)
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (Rockville, MD)
The United States of America, as represented by the Secretary of the Navy
Appl. No.: 12/064,554
Filed: August 31, 2006
PCT Filed: August 31, 2006
PCT No.: PCT/US2006/033982
371(c)(1),(2),(4) Date: October 27, 2008
PCT Pub. No.: WO2007/027860
PCT Pub. Date: March 08, 2007
Government Interests
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
This invention was made in part with Government support under Cooperative Research and Development Agreement (CRADA) Number NMR-04-1869, and amendments thereto, executed between GenVec, Inc. and the Naval Medical Research Center (NMRC). The Government may have certain rights in this invention.
